Regulatory Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry Pharmaceutical TechnologyLilly's product, known under the brand name Foundayo, has a clear route to early blockbuster status.RegulatoryMetabolic & GLP-1Read full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology Lilly’s product, known under the brand name Foundayo, has a clear route to early blockbuster status. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26Next: ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
